Abstract
Cortical GABAergic neuron dysregulation is implicated in schizophrenia (SCZ), but it remains unclear if these changes are due to altered cell proportions or per-cell mRNA changes. We analyzed bulk and cell type-specific RNAseq data from 1,302 individuals to assess SCZ- and age-associated changes in GABAergic interneurons across two neocortical regions. We found that younger SCZ cases (age < 70) showed reduced parvalbumin (PVALB) and somatostatin (SST) cell proportions, while older SCZ cases showed increased proportions compared to controls. Earlier onset SCZ, associated with more severe clinical symptoms, was linked to greater reductions in these cell types. Additionally, there was cohort-specific evidence for reduced per-cell PVALB and SST mRNA in SCZ. Our findings underscore the importance of age-stratified analyses in SCZ, suggesting that distinct pathological processes underlie GABAergic neuron dysregulation across different age- and symptom-severity groups and warranting tailored therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used data available through the PsychENCODE consortium located at https://www.psychencode.org/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors and can also be requested through the PsychENCODE consortium.
